Pharmaceuticals and Life Sciences: North American Mergers & Acquisitions Overview – Q3 2009

View this page in: Français

Despite difficult economic times and tight credit markets, capital market activity in North America in the pharma and life sciences sector has remained relatively robust over the past year. With three mega-deals completed in the first quarter of 2009—including Pfizer’s $63 billion bid for Wyeth, Roche’s $44 billion bid for the remaining stake in Genentech, and Merck & Co.’s $43 billion bid for Schering Plough—mergers and acquisitions (M&A) momentum has continued to gather steam, reaching almost 200 completed transactions by the end of the third quarter.

The following publication provides an overview of the North American M&A activity for the third quarter of 2009 for the life sciences and pharmaceutical industry.